Linked e-resources
Details
Table of Contents
Chapter 2: Neuromolecular Mechanisms of Cannabis Action
2.1 Introduction and Scope of this Chapter
2.1.1 Neuromolecular Targets of THC: The Cannabinoid Receptors
2.1.1.1 CB1 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology
2.1.1.2 CB2 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology
2.1.2 Neuromolecular Targets of THC: Beyond the Cannabinoid Receptors
2.1.3 Neuromolecular Targets of CBD
2.1.4 Neuromolecular Targets of Other Cannabinoids
2.1.4.1 Delta9-Tetrahydrocannabidivarin
2.1.4.2 Cannabinol
2.1.4.3 Delta9-Tetrahydrocannabinolic Acid
2.1.4.4 Cannabidivarin
2.1.4.5 Cannabidiolic Acid
2.1.4.6 Cannabigerol
2.1.4.7 Cannabichromene
2.1.5 Concluding Remarks
References
Chapter 3: Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review
3.1 Introduction
3.2 Neuromolecular mechanisms of action of the main phytocannabinoids
3.2.1 THC
3.2.2 CBD
3.2.3 Delta-9-THCV
3.2.4 Delta-9-THCA
3.2.5 Delta-8-THC
3.2.6 CBDV
3.2.7 CBN
3.2.8 CBG
3.2.9 CBC
3.2.10 CBDA
3.3 Neurochemical and behavioral effects of THC and CBD: Human studies
3.3.1 THC
3.3.2 CBD
3.4 Approved indications of cannabis-based products, THC and CBD
3.4.1 Cannabis-based products
3.4.2 THC
3.4.2.1 Nausea and vomiting due to chemotherapy
3.4.2.2 Appetite and decreasing weight loss associated with HIV/AIDS
3.4.2.3 Multiple sclerosis symptoms (spasticity and chronic pain)
3.4.2.4 Chronic pain (neuropathic and cancer pain)
3.4.3 CBD
3.4.3.1 Antiepileptic
3.4.3.2 Therapeutic potentials of CBD with moderate/modest evidence from RCTs
3.5 Adverse effects of THC and CBD
3.5.1 Cannabis-based products and THC
3.5.2 CBD
3.6 Conclusions
References
Chapter 4: Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models
4.1 Introduction
4.1.1 Cannabinoid Classifications
4.2 Endocannabinoids
4.3 Phytocannabinoids
4.4 Synthetic Cannabinoids
4.5 Cannabinoids in Neuromodulation
4.5.1 Cannabinoids in Epilepsy
4.5.2 Cannabinoids in Alzheimerś Disease
4.5.3 Cannabinoids in Parkinsonś Disease
4.6 Cannabinoids in Cancer
4.7 Cannabinoids in Metabolic Disorders
2.1 Introduction and Scope of this Chapter
2.1.1 Neuromolecular Targets of THC: The Cannabinoid Receptors
2.1.1.1 CB1 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology
2.1.1.2 CB2 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology
2.1.2 Neuromolecular Targets of THC: Beyond the Cannabinoid Receptors
2.1.3 Neuromolecular Targets of CBD
2.1.4 Neuromolecular Targets of Other Cannabinoids
2.1.4.1 Delta9-Tetrahydrocannabidivarin
2.1.4.2 Cannabinol
2.1.4.3 Delta9-Tetrahydrocannabinolic Acid
2.1.4.4 Cannabidivarin
2.1.4.5 Cannabidiolic Acid
2.1.4.6 Cannabigerol
2.1.4.7 Cannabichromene
2.1.5 Concluding Remarks
References
Chapter 3: Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review
3.1 Introduction
3.2 Neuromolecular mechanisms of action of the main phytocannabinoids
3.2.1 THC
3.2.2 CBD
3.2.3 Delta-9-THCV
3.2.4 Delta-9-THCA
3.2.5 Delta-8-THC
3.2.6 CBDV
3.2.7 CBN
3.2.8 CBG
3.2.9 CBC
3.2.10 CBDA
3.3 Neurochemical and behavioral effects of THC and CBD: Human studies
3.3.1 THC
3.3.2 CBD
3.4 Approved indications of cannabis-based products, THC and CBD
3.4.1 Cannabis-based products
3.4.2 THC
3.4.2.1 Nausea and vomiting due to chemotherapy
3.4.2.2 Appetite and decreasing weight loss associated with HIV/AIDS
3.4.2.3 Multiple sclerosis symptoms (spasticity and chronic pain)
3.4.2.4 Chronic pain (neuropathic and cancer pain)
3.4.3 CBD
3.4.3.1 Antiepileptic
3.4.3.2 Therapeutic potentials of CBD with moderate/modest evidence from RCTs
3.5 Adverse effects of THC and CBD
3.5.1 Cannabis-based products and THC
3.5.2 CBD
3.6 Conclusions
References
Chapter 4: Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models
4.1 Introduction
4.1.1 Cannabinoid Classifications
4.2 Endocannabinoids
4.3 Phytocannabinoids
4.4 Synthetic Cannabinoids
4.5 Cannabinoids in Neuromodulation
4.5.1 Cannabinoids in Epilepsy
4.5.2 Cannabinoids in Alzheimerś Disease
4.5.3 Cannabinoids in Parkinsonś Disease
4.6 Cannabinoids in Cancer
4.7 Cannabinoids in Metabolic Disorders